Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with

Rebecca A Russell1, Vinay K Pathak

  • 1HIV Drug Resistance Program, National Cancer Institute-Frederick, P.O. Box B, Bldg. 535, Rm. 334, Frederick, MD 21702-1201, USA.

Journal of Virology
|May 25, 2007
PubMed

Insights

Human immunodeficiency virus type 1 (HIV-1) Vif protein has two key regions, Y(40)RHHY(44) and D(14)RMR(17), that bind to host restriction factors APOBEC3G and APOBEC3F. Targeting these Vif-APOBEC3 interactions offers a potential antiviral strategy.

Area of Science:

  • Virology
  • Molecular Biology
  • Immunology

Background:

  • Human cytidine deaminases APOBEC3G (A3G) and APOBEC3F (A3F) are host restriction factors that inhibit human immunodeficiency virus type 1 (HIV-1) replication.
  • The HIV-1 Vif protein antagonizes A3G and A3F by mediating their proteasomal degradation, thus enabling viral replication.

Purpose of the Study:

  • To identify the specific regions of HIV-1 Vif responsible for binding to and antagonizing A3G and A3F.
  • To explore the potential of targeting Vif-APOBEC3 interactions for antiviral drug development.

Main Methods:

  • Extensive mutational analysis of HIV-1 Vif protein.
  • Assessment of Vif binding to A3G and A3F.
  • Evaluation of Vif's ability to suppress A3F and neutralize Vif-resistant A3G mutants.

Main Results:

  • Two distinct Vif determinants were identified: Y(40)RHHY(44) for A3G binding and D(14)RMR(17) for A3F binding.
  • Mutating the A3G-binding region enhanced Vif's suppression of A3F.
  • Vif binding to a Vif-resistant A3G mutant (D128K-A3G) depended on the Y(40)RHHY(44) region, while neutralization required the D(14)RMR(17) region.

Conclusions:

  • HIV-1 Vif utilizes distinct regions for independent interactions with A3G and A3F.
  • Interfering with Vif-APOBEC3 interactions presents a promising therapeutic strategy for controlling HIV-1 replication.